Day: February 8, 2024

CHANTILLY, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a $48 million task order on the U.S. Army’s Responsive Strategic Sourcing for Services (RS3) contract to support the software development lifecycle for command and control applications. The new contract will have a one-year base period with two one-year option periods and expands the company’s support to the U.S. Army’s RS3 mission.   “Our broad experience with systems and technology integration will be leveraged to support real-time situational awareness and decision support for the U.S. Army across the all-domain battlespace,” said Mike Kushin, president, Defense and Intelligence for Parsons. “For decades, our innovation has provided the critical interoperability, information assurance, training, and support,...

SYDNEY, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) — Iris Energy Limited (NASDAQ: IREN) (together with its subsidiaries, “Iris Energy” or “the Company”), a leading owner and operator of next-generation data centers powered by 100% renewable energy, today announces commencement of GPU cloud service with leading AI company, Poolside AI SAS (“poolside”). Key HighlightsNVIDIA H100 GPU cloud services agreement with leading AI company, poolside Contract secured following rigorous customer testing requirements Initial 3-month term and extension option for an additional 3 months at the customer’s electionIris Energy has executed a cloud service agreement with poolside for 248 NVIDIA H100 GPUs. The contract is for an initial 3-month term, with an extension option for an additional 3 months at the customer’s election. Poolside closed...

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization BioNTech secures the right to utilize Autolus’ manufacturing capacity in a cost-efficient set-up to accelerate the development of BNT211 into pivotal trials in CLDN6+ tumors BioNTech to support launch and expansion of development program of Autolus’ lead cell therapy candidate obe-cel and will receive a royalty on net sales BioNTech has co-commercialization options for Autolus’ AUTO1/22 and AUTO6NG programs BioNTech has the option to access a suite of Autolus target binders and cell programming technologies to support BioNTech’s development of in vivo cell therapy and antibody-drug conjugate candidates BioNTech agrees to invest $200...

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization BioNTech secures the right to utilize Autolus’ manufacturing capacity in a cost-efficient set-up to accelerate the development of BNT211 into pivotal trials in CLDN6+ tumors BioNTech to support launch and expansion of development program of Autolus’ lead cell therapy candidate obe-cel and will receive a royalty on net sales BioNTech has co-commercialization options for Autolus’ AUTO1/22 and AUTO6NG programs BioNTech has the option to access a suite of Autolus target binders and cell programming technologies to support BioNTech’s development of in vivo cell therapy and antibody-drug conjugate candidates BioNTech agrees to invest $200...

LAS VEGAS, Feb. 08, 2024 (GLOBE NEWSWIRE) — via IBN — Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) has officially activated the first phase of development for the Destino Ranch Project through the execution of a land use and development agreement that provides exclusive rights to use and operate on the property. The agreement will allow for the full development of phase one of the project, which will include:Site Event Plans and Permitting Site Prep and Clean Out Staff Infrastructure and Housing Temporary Power Grid Event Features and InfrastructureThe initial 68 acres were identified for the first phase of the project due to the approximately $3,000,000 in substantial infrastructure upgrades that have been invested into the property. These upgrades include:Special Event Permits Graded Roads Fencing Storage Septic Solar Landscaping/Hardscaping Water...

Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that: We have successfully dosed the first of three patients in Cohort 8 (Temferon™ at 4×10^6/kg), the last cohort of the Phase 1 dose-ranging part of the Phase 1/2 clinical trial in newly diagnosed uMGMT Glioblastoma Multiforme (TEM-GBM) patients. The second patient has been enrolled and the treatment is planned.Thus far, the preliminary data indicate no dose-limiting toxicities related to Temferon have been detected in any of 22 treated...